Delgocitinib Process Patent: Understanding US10822354

What is Patent US10822354 about?

Patent US10822354 describes a process for preparing delgocitinib, an active pharmaceutical ingredient. This patent is relevant to the manufacturing of delgocitinib, a Janus kinase (JAK) inhibitor used for treating certain medical conditions.

How is Delgocitinib Made According to this Patent?

The patent details a specific chemical synthesis route for delgocitinib. This process is designed to yield the drug substance with desired purity and efficiency. The exact chemical steps and conditions are proprietary information outlined within the patent document.

When Does the Delgocitinib Process Patent Expire?

Patent expiration dates are crucial for understanding market exclusivity. For patent US10822354, the expiration date can be determined by consulting patent databases. DrugPatentWatch.com offers resources to track patent expiration timelines for pharmaceutical compounds and their associated manufacturing processes.

Who Holds the Patent for the Delgocitinib Process?

The ownership of patent US10822354 is assigned to the entity that developed and filed the patent application. This information is publicly available through patent office records. Typically, the patent holder would be the pharmaceutical company that developed or acquired the rights to delgocitinib.

Are There Other Patents Related to Delgocitinib?

Pharmaceutical development often involves multiple patents covering different aspects of a drug, including its composition, formulation, method of use, and manufacturing processes. It is common for a drug like delgocitinib to be protected by a portfolio of patents. DrugPatentWatch.com can provide a comprehensive view of related patent filings.

What is the Significance of a Process Patent for Delgocitinib?

Process patents protect the specific methods used to manufacture a drug. This can be important for controlling the supply chain and preventing competitors from using the same efficient or cost-effective manufacturing techniques, even if the main composition of matter patent has expired or is nearing expiration.

What are the Implications for Generic Drug Manufacturers?

For generic manufacturers, understanding process patents is vital. While they may seek to produce a generic version of delgocitinib after the primary patent expires, they must also ensure their manufacturing process does not infringe on any active process patents. Successfully challenging or waiting for process patents to expire is a key step in bringing a generic drug to market.

Where Can I Find More Information on Delgocitinib Patents?

Detailed information on patent US10822354, including its full text, status, and legal history, can be found through official patent office websites and specialized patent search platforms. DrugPatentWatch.com is a valuable resource for researching pharmaceutical patents, including those related to delgocitinib and its manufacturing [1].

Sources:

1. DrugPatentWatch.com